Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Stage III Gastric Cancer, Stage IV Gastric Cancer
About this trial
This is an interventional treatment trial for Stage III Gastric Cancer
Eligibility Criteria
Inclusion Criteria: Diagnosis of metastatic or unresectable carcinoma of the stomach Measurable disease No brain metastasis Performance status - Karnofsky 70-100% More than 3 months WBC at least 3,000/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 10 g/dL No history of any bleeding disorders Bilirubin no greater than 1.5 mg/dL Transaminases no greater than 2 times normal Creatinine no greater than 1.5 mg/dL Creatinine clearance at least 60 mL/min No history of peptic ulceration or gastrointestinal bleeding No active infection No seizure disorder Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative No other serious concurrent illness that would preclude study entry No medical, social, or psychological factors that would preclude study entry No prior chemotherapy No prior radiotherapy More than 4 weeks since prior major surgery Prior incomplete resection allowed No other prior antitumor treatment
Sites / Locations
- University of Southern California
Arms of the Study
Arm 1
Experimental
Treatment
Patients receive bryostatin 1 IV over 72 hours on days 1-3 followed by cisplatin IV over 1 hour on day 4. Treatment repeats every 3 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.